Allergan Inc. (AGN) CEO Resigns From Edwards Lifesciences (EW)' Board

Edwards Announces Board Change

IRVINE, Calif., Oct. 3, 2014 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced that David E.I. Pyott, a member of the company's Board of Directors, has submitted his resignation, effective today, in order to devote more time to his role as chairman and chief executive officer of Allergan, Inc.

Edwards Lifesciences logo.
"The board and I are truly appreciative of David's service and commitment to Edwards during the last 14 years," said Michael A. Mussallem, Edwards' chairman and CEO. "David's extensive global experience in leadership roles at innovative health and nutrition companies made him a valuable resource for our company. He has been a trusted partner and brought important expertise to Edwards in delivering novel therapies to address the needs of patients. We wish him the best and thank him for the significant role he has played in Edwards' growth and success."

Pyott joined Edwards' board of directors in 2000, when Edwards was established as an independent, publicly-held corporation.

About Edwards Lifesciences

Edwards Lifesciences is the global leader in the science of heart valves and hemodynamic monitoring. Driven by a passion to help patients, the company partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring, enabling them to save and enhance lives. Additional company information can be found at

Edwards, Edwards Lifesciences and the stylized E logo are trademarks of Edwards Lifesciences Corporation.

Logo -

SOURCE Edwards Lifesciences Corporation

Suggested Articles

The FDA slapped a partial clinical hold on the phase 2/3 study of Inovio’s COVID-19 vaccine because it has “additional questions” about the trial.

Preclinical inflammatory disease biotech Ilias Biologics has grabbed a $20.6 million funding round as it eyes a 2021 human test of its leading asset.

Aligos Therapeutics is shooting for a $100 million IPO to help drive its early work on a functional cure for chronic hepatitis B as well as COVID-19.